Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Investing.com - Adaptimmune Therapeutics reported on Monday first quarter earnings that beat analysts' forecasts and revenue that ...

Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Technology, Consumer Services and Telecoms ...

Adaptimmune Therapeutics PLC是一家临床阶段的生物制药公司。该公司专注于为癌症患者提供细胞疗法。它为实体瘤开发 T 细胞疗法，并报告了七种实体瘤适应症的临床反应（根据 RECIST 1.1）。它的平台能够识别癌症靶点，发现和开发对这些靶点有活性的细胞治疗候选物 ...

Adaptimmune Therapeutics has a price-to-earnings (P/E) ratio of -0.240 (TTM). This compares to an industry average of 25.990. The P/S ratio for Adaptimmune Therapeutics is currently 0.652 (TTM). What ...

A summary for the Adaptimmune Therapeutics Plc share. Signals range from Strong Buy, Buy, Neutral, Sell to Strong Sell. It also offers detailed technical analysis based on the buy/sell signals of ...

Adaptimmune Therapeutics PLC (NASDAQ:ADAP), currently trading near its 52-week low of $0.05 and down over 95% in the past year, ...

Adaptimmune Therapeutics (ADAPY) has delivered a -94.990% change over the past year, with a 52-week range between 0.020 and 0.685. What Is the Average Daily Trading Volume of Adaptimmune Therapeutics ...